Cadila Pharmaceuticals Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is VENLAFAXINE HYDROCHLORIDE USP (PROCESS-2), with a corresponding US DMF Number 29718.
Remarkably, this DMF maintains an Active status since its submission on September 23, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of October 08, 2015, and payment made on September 10, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II